684 patents
Utility
CD3 Binding Antibodies
18 Jan 24
The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Filed: 18 Jan 23
Utility
Agonistic ANTI-IL-2R Antibodies and Methods of Use
18 Jan 24
Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
Filed: 29 Aug 23
Utility
Variants of Tissue Inhibitor of Metalloproteinase Type Three (TIMP-3), Compositions and Methods
11 Jan 24
There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
Jeonghoon SUN, Jason Charles O'NEILL, Randal R. KETCHEM, Randy Ira HECHT, Edward J. BELOUSKI, Mark Leo MICHAELS
Filed: 28 Aug 23
Utility
Antibody Constructs for CDH19 and CD3
11 Jan 24
The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell.
Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
Filed: 19 Sep 22
Utility
Materials and Methods for Protein Processing
11 Jan 24
Described herein are materials and methods for protein production and analysis.
Sreekanth SURAVAJJALA, Jennifer Lynn LIPPENS
Filed: 1 Nov 21
Utility
Predicting Shelf Life Stability of Lyophilized Drug Products
11 Jan 24
A method of computational modeling to predict stability of a lyophilized drug product includes receiving model parameters describing a virtual cake, a virtual vial, a virtual stopper, and a virtual ambient environment.
Ron Christopher Kelly, Mary Chaves, Marc A. Caporini, Fabrice Schlegel
Filed: 30 Aug 21
Utility
Enantioselective Alkenylation of Aldehydes
4 Jan 24
KYLE D. BAUCOM, MICHAEL T. CORBETT, SHENG CUI, NEIL F. LANGILLE, ANDREAS RENE ROTHELI, ROBERTO PROFETA, AUSTIN G. SMITH
Filed: 23 Nov 21
Utility
Heavy Chain Antibodies Binding to Folate Receptor Alpha
4 Jan 24
Anti-Folate Receptor Alpha (FOLR1) heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of Folate Receptor Alpha (FOLR1).
Brian Avanzino, Katherine Harris, Hannes Kehm, Nathan Trinklein
Filed: 17 Nov 21
Utility
Novel Linkers of Multispecific Antigen Binding Domains
4 Jan 24
The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic.
Timothy RILEY, Fernando GARCES, Zhulun WANG, Bram Estes, Darren L. Bates
Filed: 9 Nov 21
Utility
Computer Surrogate Model to Predict the Single-phase Mixing Quality In Steady State Mixing Tanks
4 Jan 24
Systems and methods of using a surrogate machine learning model, based on a CFD model, to predict the mixing quality in steady state mixing tanks are provided.
Emad Ghadirian Hoseinabadi, William Leigh Johnson
Filed: 29 Sep 21
Utility
In-process Verification of Calibration Status of PH Probes
28 Dec 23
Automated systems and methods for low-pH viral inactivation include adding an elution pool to a first vessel with an acid.
Venkatesh Natarajan, Marco DeLiso, Jeremy Aaron Bezaire, Andrew Cavigli, Jeremy S. Conner, Jon Hunter, Sidney Pehrson, Sarah Whetstone
Filed: 9 Nov 21
Utility
Methods for Decreasing Mortality Risk and Improving Health
28 Dec 23
The disclosure provides methods for decreasing mortality risk and/or improving health in a subject.
Kári Stefánsson, Daniel Gudbjartsson, Magnús Úlfarsson, Thjodbjorg Eiriksdottir
Filed: 15 Nov 21
Utility
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
21 Dec 23
The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles.
Winnie SOHN, Zachary JONES, Helina KASSAHUN
Filed: 4 Nov 21
Utility
Gas Permeable Sealing Member for Drug Container and Methods of Assembly
21 Dec 23
Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed.
Cheng-Chieh Chou, Mingda Eu, Ren-Yo Forng, Wael Mismar
Filed: 28 Apr 23
Utility
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 And/or PD-L1 Inhibitor
21 Dec 23
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.
James J. CAMPBELL, Rajinder SINGH, Jeffrey K. HARRISON
Filed: 3 May 23
Utility
Heterocyclic Spiro Compounds and Methods of Use
21 Dec 23
BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
Filed: 26 Oct 21
Utility
Polypeptide Constructs Binding to CD3
21 Dec 23
The invention relates to a polypeptide or polypeptide construct comprising: a binding domain binding to an extracellular epitope of the human CD3s chain comprising or consisting of a VH region and a VL region, wherein i) the VH region comprises: a CDR-H1 sequence of X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I; a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, S, or E; and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY, where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W or F; and X4 is W, F or Y; and ii) wherein the VL region comprises: a CDR-L1 sequence of X1 SSTGAVTX2X3X4YX5N, where X1 is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y and X5 is P or A; a CDR-L2 sequence of X1TX2X3X4X5X6; where X1 is G or A; X2 is K, D, or N; X3 is F, M or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S; and a CDR-L3 sequence of X1LWYSNX2VW, where X1 is V, A, or T; and X2 is R or L; and iii) wherein one or more of CDR sequences of the VH region of i) and/or of the VL region of ii) comprise one amino acid substitution or a combination thereof selected from X24V and X24F in CDR-H1; D15, and X116A in CDR-H2; H1, X12E, F4, and N6 in CDR-H3; and X11L and W3 in CDR-L3.
Doris Rau, Tobias Raum, Partrick Hoffmann, Markus Muenz, Matthias Klinger, Virginie Naegele, Lisa Winkel, Pavan Ghattyvenkatakrishna, Joon Hoi Huh, Arnold McAuley, Sekhar Kanapuram
Filed: 8 Nov 21
Utility
Methods for Administering Therapeutic Doses of Bispecific T-cell Engaging Molecules for the Treatment of Cancer
14 Dec 23
The present invention relates to methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer in a patient.
Adam B. MCCULLOUGH, Hosein KOUROS-MEHR, Peter KUFER, Mark SALVATI, Alexander C. MINELLA, Dirk NAGORSEN, Vijay UPRETI, Mukul MINOCHA, Brett HOUK
Filed: 15 Sep 21
Utility
Robotic System for Performing Pattern Recognition-based Inspection of Pharmaceutical Containers
14 Dec 23
A robotic inspection platform comprises a robotic arm, an imager, and a controller.
Dmitry Fradkin, Thomas Clark Pearson, Neelima Chavali, Erwin Freund
Filed: 18 Aug 23
Utility
Titration Methods for Detecting Polyvinyl Sulfonate (PVS) In Buffers
14 Dec 23
The disclosure provides methods, including automated methods, to detect levels of polyanions such as polyvinyl sulfonates in fluids such as buffers by complexometric or titration-based techniques.
Robert Joseph Soto
Filed: 15 Oct 21